ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PRLD vs ENTA // EV/EBITDA & P/E VALUATION

Prelude Therapeutics Incorporated (NASDAQ) VS. Enanta Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: PRLD 4 — ENTA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRLD VS. ENTA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PRLD ENTA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -17.23% -9.91% -7.32 ENTA /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 73.40% -3.40% +76.80 PRLD /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 PRLD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.1 36.6 +12.45 PRLD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $327.2M $324.7M $2.4M PRLD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PRLD REV ENTA REV PRLD GROSS % ENTA GROSS % PRLD FCF ENTA FCF
FY 2025 $12.1M $65.3M — — -$56.4M -$32.2M
FY 2024 $7.0M $67.6M — — -$103.7M -$96.7M
FY 2023 $0 $79.2M — — -$107.1M -$103.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRLD // BETA —
ENTA // BETA —